• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    NorthStrive Defense Tech Executes Definitive Exclusive License Agreement with Florida State University Research Foundation for Multi-Domain Drone Payload Technology Across Defense, Aerospace and Maritime Applications

    7/13/26 7:30:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELAB alert in real time by email
    • Definitive license agreement formalizes exclusive, worldwide, sublicensable rights to patented multi-domain drone payload technology for aerospace and defense applications
    • Agreement follows the binding term sheet and sponsored research agreement announced earlier this year
    • License covers U.S. Patent No. 12,291,334 and related know-how, with a multi-year development plan targeting prototype completion, non-dilutive funding applications, and first commercial sale

    NEWPORT BEACH, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- NorthStrive Defense Tech LLC ("NorthStrive Defense Tech"), a wholly owned subsidiary of PMGC Holdings Inc. (the "Company") (NASDAQ:ELAB) formed to license and commercialize defense technologies, starting with technology developed at Florida State University ("FSU"), today announced that it has executed a definitive Standard Exclusive License Agreement with Know-How (the "License Agreement") with the Florida State University Research Foundation ("FSURF"), a not-for-profit corporation and direct support organization of Florida State University, for certain patent rights and related know-how covering a novel multi-domain drone payload technology.

    The definitive License Agreement follows the parties’ exclusive option agreement announced on April 6, 2026 and binding term sheet announced on June 8, 2026, advancing the arrangement to a definitive, executed license.

    Licensed U.S. Patent No. 12,291,334 covers a next-generation drone system designed to transport payloads across air and water environments. The technology enables an aerial vehicle to autonomously transport a cable-suspended payload through water while maintaining flight above the surface, leveraging buoyancy-assisted transport to potentially improve payload efficiency compared to traditional air-only drone systems.

    Aligned With Rising Defense Demand for Multi-Domain Unmanned Systems

    NorthStrive Defense Tech believes the licensed technology has potential real-world applications in defense and dual-use environments where unmanned systems are increasingly being developed to operate across maritime, aerial, and payload-delivery missions. Recent public news and reporting has highlighted this growing need, including coverage of the United States, United Kingdom, and Australia advancing underwater drone technologies through the AUKUS defense partnership, and reporting on the U.S. Navy’s pursuit of unmanned surface vessels capable of carrying large payloads over long distances in support of manned warships.1, 2 NorthStrive Defense Tech believes these developments underscore a broader defense-market shift toward multi-domain unmanned platforms, maritime autonomy, and mission-flexible systems that can operate in complex air and water environments.

    Under the License Agreement, NorthStrive Defense Tech has obtained an exclusive, worldwide, sublicensable license within the aerospace and defense technologies field to make, have made, use, sell, have sold, sublicense, and import licensed products covered by U.S. Patent No. 12,291,334 and associated know-how. As the exclusive licensee, NorthStrive Defense Tech serves as the single point of access for defense and dual-use development, integration, and sublicensing of the technology.

    Key terms of the License Agreement include:

    • Licensed Rights: U.S. Patent No. 12,291,334 and related know-how, including software, methods, data, and algorithms related to the control and navigation of the multi-domain parcel transportation system
    • Field of Use: Aerospace and defense technologies
    • Territory: Worldwide
    • Exclusivity: Exclusive (patent rights); non-exclusive (know-how)
    • Sublicensing Rights: Yes
    • License Term: Life of the patent, with the license becoming perpetual and fully paid-up following expiration of the applicable royalty term
    • Financial Terms: Customary license fees, annual maintenance fees, earned royalties on net sales, minimum annual royalties, and sublicensing revenue payments, as further described in the License Agreement
    • Development Obligations: Commercially reasonable development efforts under a multi-year development plan, including making a working prototype, submitting non-dilutive funding applications, achieving first commercial sale, establishing manufacturing capability, and reaching cumulative net sales milestones

    The License Agreement also includes customary provisions regarding diligence milestones, reporting obligations, indemnification, insurance, confidentiality, and dispute resolution.

    Sponsored Research to Advance a Working Prototype

    In connection with the license, NorthStrive Defense Tech previously entered into a sponsored research agreement with FSURF to fund and collaborate on additional research and development activities intended to advance the technology toward a working prototype and potential commercial-grade units. That sponsored research program remains ongoing.

    NorthStrive Defense Tech cannot provide any assurances on the commercial success of this technology. NorthStrive Defense Tech was formed to license and commercialize the FSU technology while also pursuing additional strategic investments in, and acquisitions of, complementary technologies, assets and companies. The Company intends to continue evaluating opportunities to expand its portfolio of aerospace, defense, autonomous systems, and dual-use technologies through licensing, acquisition, sponsored research, and strategic collaboration.

    NorthStrive Defense Tech’s entry into the License Agreement was disclosed in the Company’s Current Report on Form 8-K filed with the United States Securities and Exchange Commission ("SEC") on July 7, 2026. A copy of the License Agreement was included as an exhibit therein.

    About NorthStrive Defense Tech LLC

    NorthStrive Defense Tech LLC is a wholly owned subsidiary of PMGC Holdings Inc. focused on identifying, acquiring, licensing, developing, and commercializing advanced defense technologies, with an emphasis on drone, autonomous systems, aerospace, and dual-use applications.

    About PMGC Holdings Inc.

    PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit www.pmgcholdings.com.

    Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "believes," "expects," "plans," "potential," "would" and "future" or similar expressions such as "look forward" are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC’s filings with the SEC, including the "Risk Factors" section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

    IR Contact: IR@pmgcholdings.com

    The Company and NorthStrive Defense Tech undertake no obligation to update any forward-looking statements, except as required by law.

    References

    1. BBC News — US, UK and Australia to develop underwater drone technology. Reports the AUKUS Pillar Two program to develop uncrewed undersea vehicle (UUV) technology to help protect undersea cables and seabed infrastructure. Cited as third-party market context only; NorthStrive Defense Tech is not a participant in AUKUS. Source: https://www.bbc.com/news/articles/c5y8wjvd1ypo

    2. USNI News — Navy Seeks New Fast Attack Surface Drone Design, July 28, 2025. Supports U.S. Navy demand for unmanned surface vessels capable of carrying large payloads over long distances in support of manned warships. Source: https://news.usni.org/2025/07/28/navy-seeks-new-fast-attack-surface-drone-design



    Primary Logo

    Get the next $ELAB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELAB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ELAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NorthStrive Defense Tech Executes Definitive Exclusive License Agreement with Florida State University Research Foundation for Multi-Domain Drone Payload Technology Across Defense, Aerospace and Maritime Applications

    Definitive license agreement formalizes exclusive, worldwide, sublicensable rights to patented multi-domain drone payload technology for aerospace and defense applicationsAgreement follows the binding term sheet and sponsored research agreement announced earlier this yearLicense covers U.S. Patent No. 12,291,334 and related know-how, with a multi-year development plan targeting prototype completion, non-dilutive funding applications, and first commercial sale NEWPORT BEACH, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- NorthStrive Defense Tech LLC ("NorthStrive Defense Tech"), a wholly owned subsidiary of PMGC Holdings Inc. (the "Company") (NASDAQ:ELAB) formed to license and commercialize def

    7/13/26 7:30:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NorthStrive Biosciences to Advance EL-22 Manufacturing Characterization with Quantitative FACS Analysis of Latent Myostatin Antigen Expression

    Independent flow cytometry (FACS) study will quantify latent myostatin antigen expression on NorthStrive-manufactured Lactobacillus casei and establish comparability against EL-22 material previously manufactured by MOA Life Plus Co. Ltd. Work is intended to strengthen EL-22 product identity and manufacturing consistency as NorthStrive advances a differentiated engineered probiotic designed to help preserve muscle during weight loss, including with GLP-1 receptor agonists NEWPORT BEACH, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. ("NorthStrive Biosciences"), a subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company"), today announced plans to ini

    7/10/26 7:30:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMGC Holdings Inc. Announces Merger of AGA Precision Systems into A&B Aerospace

    Strategic consolidation of two precision manufacturing portfolio companies expected to streamline operations, shared resources, and strengthen the companies’ aerospace manufacturing platform NEWPORT BEACH, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company") today announced that it has merged AGA Precision Systems LLC ("AGA") into A&B Aerospace, Inc. ("A&B Aerospace"), with A&B Aerospace expected to be the surviving operating entity. The merger is designed to simplify PMGC’s aerospace precision manufacturing platform by consolidating two related businesses under one corporate structure. Following the merger, AGA will cease to exist as a sep

    7/6/26 7:30:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Bensler Graydon

    4 - PMGC Holdings Inc. (0001840563) (Issuer)

    6/3/26 4:01:11 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Parry Jeffrey

    4 - PMGC Holdings Inc. (0001840563) (Issuer)

    6/3/26 8:09:25 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Kovalyov George

    4 - PMGC Holdings Inc. (0001840563) (Issuer)

    6/2/26 8:10:59 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    SEC Filings

    View All

    PMGC Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - PMGC Holdings Inc. (0001840563) (Filer)

    7/9/26 4:01:54 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMGC Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - PMGC Holdings Inc. (0001840563) (Filer)

    7/7/26 5:18:15 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMGC Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PMGC Holdings Inc. (0001840563) (Filer)

    7/1/26 7:31:32 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Financials

    Live finance-specific insights

    View All

    PMGC Holdings (NASDAQ: ELAB) Acquires A&B Aerospace, Inc.

    Precision machining and aerospace, defense manufacturing company contracted by long standing Tier 1 customers that include Boeing, Honeywell International Inc., and Moog Inc.*AS9100D and ISO 9001:2015 certified NEWPORT BEACH, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company"), a diversified holding company currently executing a targeted roll-up strategy in U.S.-based precision manufacturing companies, has acquired A&B Aerospace, Inc. ("A&B Aerospace" or "A&B"), Founded in 1948, A&B Aerospace is a precision machining and aerospace manufacturing company specializing in high-tolerance parts and assemblies for the aerospace industry. Headquart

    5/13/26 4:03:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NorthStrive Defense Tech Acquires Multi-Domain Drone Payload Technology Option for Defense and Commercial Applications

    NEWPORT BEACH, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- NorthStrive Defense Tech LLC ("NorthStrive Defense Tech"), a wholly-owned subsidiary of PMGC Holdings Inc. (the "Company") (NASDAQ:ELAB), today announced it has acquired rights to a novel drone technology through an exclusive option agreement ("Option Agreement") with a corporation. The Option Agreement provides NorthStrive Defense Tech with an exclusive option, within the aerospace and defense technologies field ("Field"), to get an exclusive license as to certain patent rights for U.S. Patent No. 12,291,334, covering a next-generation drone system designed to transport payloads across air and water environments. The option ("Opti

    4/6/26 7:30:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMGC Holdings Inc. Announces the Acquisition of SVM Machining, Inc.

    NEWPORT BEACH, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company"), a diversified public holding company announced that it has completed the acquisition of SVM Machining, Inc. ("SVM"). Founded in 1997 by Mark Serpa, SVM (aka Silicon Valley Manufacturing) is a Northern California-based ISO 9001:2015 Certified CNC precision machining and manufacturing services company serving medical, aerospace, biotech & pharmaceutical, semiconductor, and transportation markets. This transaction represents PMGC's third California based CNC machine shop acquisition to date, expanding PMGC's growing footprint in precision manufacturing and furthering its stra

    2/3/26 7:30:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Leadership Updates

    Live Leadership Updates

    View All

    PMGC Holdings Inc. Expands Investment & M&A Efforts, Actively Seeking Acquisitions and Investments Through Strategic Sponsorship of TCA Venture Group

    NEWPORT BEACH, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the "Company" or "PMGC," "our," or "we") (NASDAQ:ELAB), a diversified holding company, is proud to announce its annual sponsorship of TCA Venture Group's ("TCA") Orange County network for 2025. As a Southern California Network Sponsor, PMGC is actively pursuing investments and M&A opportunities to strengthen its portfolio while fostering local business growth and expanding its market presence. TCA Venture Group (formerly known as Tech Coast Angels) is one of the largest and most active angel investor networks in the United States. With a history spanning over 25 years, TCA has been instrumental in funding early-s

    2/27/25 8:00:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD

    Professor of Medicine at the University of California, Los Angeles (UCLA), where he serves as Director of the UCLA Metabolism Research Theme.Over 180 publications in the field of obesity & metabolism, along with multiple NIH-funded projects as Principal Investigator.Dr. Shirihai is a renowned researcher regularly invited as a keynote speaker at annual scientific conferences and has consulted for Johnson & Johnson, Bayer, AstraZeneca and Pfizer, among other healthcare companies. NEWPORT BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the appointment of Orian Shirihai, MD, PhD, t

    7/30/24 9:00:26 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs

    NEWPORT BEACH, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the formation of a new Scientific Advisory Board to support the advancement of EL-22, a first-in-class engineered probiotic approach, to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. "We are honored to be forming a Scientific Advisory Board with renowned members that possess deep and complementary knowledge in metabolic diseases, obesity, weight management, muscle preservation and physical function in addition to significant experience in clinical

    6/14/24 9:00:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Elevai Labs Inc.

    SC 13G - Elevai Labs Inc. (0001840563) (Subject)

    11/14/24 5:53:26 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Elevai Labs Inc.

    SC 13G - Elevai Labs Inc. (0001840563) (Subject)

    10/2/24 4:01:03 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Elevai Labs Inc.

    SC 13G - Elevai Labs Inc. (0001840563) (Subject)

    10/1/24 4:01:02 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care